TICKERNERD
Menu
TSHATSHAHealthcare · Biotechnology

TSHA Stock Forecast: Taysha Gene Therapies, Inc. Price Predictions for 2026-2027

Last close, 11 Sept 2026
$5.02
−2.71% on the day

The 12 Wall Street analysts covering Taysha Gene Therapies, Inc. hold a median 12-month price target of $13 — +149.0% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 42 of 100 as at 12 Sept 2026 — in the lower half.

Market cap
$1.6B
Ticker Nerd rank
42 / 100
Median analyst target
$13
Analysts covering
12
Revenue$0.0−100.0% y/y
Operating income−$50.8M
Net income−$46.6M
Free cash flow−$40.4M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−9.9%
1M
−24.9%
YTD
−8.7%
1Y
+54.9%
From 52W high
−28.1%
From 52W low
+77.4%
$2.83
$6.98
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

TSHA stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Taysha Gene Therapies, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 12 Sept 2026
42 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Momentum
80
Quality
74
Value
61
Accruals
47
Revisions
43
Issuance
42
Size
39
Growth
25
Volatility
16

Momentum (80): The shares have been drifting up relative to others.

Volatility (16): The share price moves around a lot.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

TSHA stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on TSHA, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$5.00$10.00$15.00$20.00Oct 25Jan 26Apr 26Jul 26TSHAHigh $19Median $13Low $10

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says12 analysts
12 Buy0 Hold0 Sell
Low $10Median $13High $19

The green dot is the last close — the median target sits +149.0% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
21 July 2026Goldman SachsMaintainsBuy$11 → $13
21 July 2026Goldman SachsMaintainsBuy—
2 July 2026CitizensReiteratesMarket Outperform$11
2 July 2026CitizensReiteratesMarket Outperform—
30 June 2026BairdMaintainsOutperform$12 → $15
30 June 2026BairdMaintainsOutperform—
30 June 2026NeedhamMaintainsBuy—
30 June 2026NeedhamMaintainsBuy$12
23 June 2026B of A SecuritiesMaintainsBuy—
23 June 2026BMO CapitalMaintainsOutperform—
23 June 2026CitizensMaintainsMarket Outperform—
22 June 2026NeedhamMaintainsBuy—
6 Apr 2026Canaccord GenuityMaintainsBuy—
19 Mar 2026Chardan CapitalMaintainsBuy—
19 Mar 2026NeedhamMaintainsBuy—
3 Mar 2026NeedhamReiteratesBuy—
6 Jan 2026Chardan CapitalMaintainsBuy—
5 Jan 2026Wells FargoMaintainsOverweight—
5 Nov 2025Chardan CapitalMaintainsBuy—
5 Nov 2025CitizensMaintainsMarket Outperform—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. TSHA appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

TSHA vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 11 Sept 2026, Taysha Gene Therapies, Inc. returned +54.9% against +17.5% for the S&P 500, dividends included.

TSHA vs S&P 500, last 12 monthsTotal return, rebased to 100
80100120140160180200220Oct 25Jan 26Apr 26Jul 26TSHAS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

TSHA analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
0
Analysts cutting
3
Fundamentals

Taysha Gene Therapies, Inc. (TSHA) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
2.5×

Cheaper than 69% of US stocks

Price / sales
298.2×

Cheaper than 3% of US stocks

Price / book
6.8×

Cheaper than 14% of US stocks

EV / EBITDA
−8.1×

Cheaper than 83% of US stocks

Growth & margins
Revenue growth (YoY)
−100.0%

Higher than 1% of US stocks

Earnings growth (YoY)
−100.0%

Higher than 1% of US stocks

Gross margin
—
Operating margin
−2792.3%

Higher than 4% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−47.1%

Higher than 22% of US stocks

Return on assets
−23.8%

Higher than 17% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Taysha Gene Therapies, Inc. (TSHA) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Taysha Gene Therapies, Inc. has a market value of $1.6B and an enterprise value of $1.2B.

  • Revenue in the twelve months to 30 June 2026: $5.5M. The latest quarter shrank 100.0% year on year.

  • Net income over the same four quarters: −$149.6M, a −2728.0% net margin.

  • Free cash flow in the twelve months to 30 June 2026: −$135.6M.

  • Shares outstanding: 325.3M.

  • Trailing P/E: 2.5×; forward P/E: −10.9× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Taysha Gene Therapies, Inc. employs 99 people — $55K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 14 Sept 2026

Data provided by Twelve Data

Peers

TSHA vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
TSHATaysha Gene Therapies, Inc.$1.6B
42
INBXInhibrx Biosciences, Inc.$1.6B
27
ANABAnaptysBio, Inc.$1.6B
99
FTREFortrea Holdings, Inc.$1.6B
97
SNDXSyndax Pharmaceuticals, Inc.$1.6B
61
FBRXForte Biosciences, Inc.$1.6B
—
NTLAIntellia Therapeutics, Inc.$1.6B
51

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Taysha Gene Therapies, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest TSHA news & analysis

Taysha Gene Therapies: A Bull Case That Does Not Require The Fastest Approval

Seeking Alpha · 11 Sept 2026positive

Seeking Alpha discusses a bull case for Taysha Gene Therapies based on TSHA-102 for Rett syndrome, noting durable early functional gains and a $455.4M cash runway into H2 2028 that supports pivotal data collection and manufacturing scale-up without depending on accelerated regulatory filing. The article highlights pivotal efficacy, safety, and manufacturing qualification as key remaining inflection points.

Why it matters — TSHA watchers would care because the funding runway and clinical progress for TSHA-102 define the company's near-term value without reliance on rapid regulatory approval.

These 3 Risky Stocks Could Be Sitting on 100% Upside

MarketBeat · 7 Sept 2026neutral

MarketBeat published an article highlighting speculative, high-upside stocks that could potentially see significant gains amid a market hovering near all-time highs. The piece notes that with many established firms facing stretched valuations and consumer reticence, investors may turn to riskier plays for growth.

Why it matters — Taysha Gene Therapies is mentioned among risky, speculative stocks with potential upside, which could draw investor attention to the company as a high-upside play.

Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewsWire · 4 Sept 2026neutral

Taysha Gene Therapies announced that on September 1, 2026, its Compensation Committee granted five new employees restricted stock units representing 314,000 shares and an option to purchase 92,400 shares under the company's 2023 Inducement Plan. The grants were made as an inducement material to the individuals joining the company, in accordance with Nasdaq Listing Rule 5635(c)(4).

Why it matters — This share-based inducement grant signals new staff additions and equity activity for TSHA, which investors and stock watchers track for corporate governance and employee-compensation disclosures.

Taysha Gene Therapies, Inc. (TSHA) Q2 2026 Earnings Call Transcript

Seeking Alpha · 12 Aug 2026neutral

Taysha Gene Therapies, Inc. held its Q2 2026 earnings call, and Seeking Alpha published the full transcript of the call. The item provides the conference call discussion for that reporting period.

Why it matters — A TSHA watcher would review the transcript for management's commentary on the company's latest quarterly results and outlook.

Taysha Gene Therapies Q2 Earnings Call Highlights

MarketBeat · 12 Aug 2026positive

Taysha Gene Therapies reported during its Q2 earnings call that it has completed dosing in the REVEAL pivotal trial and ASPIRE trial for TSHA-102, its gene therapy candidate for Rett syndrome. The company is also preparing for a potential biologics license application submission.

Why it matters — Completion of dosing in both trials brings TSHA-102 closer to a regulatory submission, a key milestone for Taysha's lead pipeline candidate.

FAQ

Frequently asked questions about TSHA stock

What is the TSHA stock price forecast for 2026-2027?

The 12 Wall Street analysts covering Taysha Gene Therapies, Inc. have a median 12-month price target of $13, with estimates ranging from $10 to $19. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is TSHA stock a buy right now?

Of the 12 analysts covering Taysha Gene Therapies, Inc., 12 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Taysha Gene Therapies, Inc. 42 out of 100 across roughly 4,600 US stocks as at 12 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank TSHA?

As at 12 Sept 2026, Taysha Gene Therapies, Inc. ranks 42 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (80 of 100).

Will TSHA stock go up?

No one can know that. What the data says: the median 12-month target from 12 analysts implies +149.0% from the last close, and Ticker Nerd's factor model ranks Taysha Gene Therapies, Inc. 42 out of 100 as at 12 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the TSHA stock forecast for 2030?

No analyst covering Taysha Gene Therapies, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for TSHA are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $10 to $19 over the next 12 months.

How has TSHA stock performed over the past year?

Taysha Gene Therapies, Inc. returned +54.9% over the 12 months to 11 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Taysha Gene Therapies, Inc. do?

Taysha Gene Therapies, Inc. is a clinical-stage biotechnology company focused on developing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system.

What is the latest news on TSHA?

The most recent item we track (Seeking Alpha, 11 Sept 2026): "Taysha Gene Therapies: A Bull Case That Does Not Require The Fastest Approval". Seeking Alpha discusses a bull case for Taysha Gene Therapies based on TSHA-102 for Rett syndrome, noting durable early functional gains and a $455.4M cash runway into H2 2028 that supports pivotal data collection and manufacturing scale-up without depending on accelerated regulatory filing. The article highlights pivotal efficacy, safety, and manufacturing qualification as key remaining inflection points.

Company

About Taysha Gene Therapies, Inc.

Taysha Gene Therapies, Inc. is a clinical-stage biotechnology company focused on developing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system. Taysha Gene Therapies works on treatments designed to address the genetic root causes of rare neurological disorders, with a pipeline that includes programs for Rett syndrome, giant axonal neuropathy, CLN1 disease, CLN7 disease, SLC13A5 deficiency, fragile X syndrome, angelman syndrome, and tauopathies. The company’s current work centers on advancing its lead clinical programs and translating AAV gene therapy platforms into potential disease-modifying medicines for underserved patient populations. Based in Dallas, Texas, Taysha Gene Therapies operates within the broader biotechnology sector, where it contributes to the development of specialized therapies for rare central nervous system disorders.

CEO Mr. Sean P. Nolan · 99 employees · United States · https://www.tayshagtx.com